Articles related to OBESITY/WEIGHT MANAGEMENT

Pfizer’s diabetes drug, danuglipron, demonstrates comparable weight loss to Novo Nordisk’s Ozempic in a recent mid-stage trial. Explore how this breakthrough could shape the future of type 2 diabetes treatment and weight loss market.

Explore four decades of research illustrating the biphasic growth patterns in fetuses of diabetic and obese women, an essential yet overlooked factor in preventing childhood obesity. The comprehensive findings may redefine your approach to perinatal care and shape healthier futures for your patients.

Study Reveals Different Effects of Antipsychotics on Weight Gain: Key Findings for Physicians A new study analyzed the impact of different antipsychotic medications on weight gain, emphasizing the importance of considering dose and specific drugs for individual patients. The study provides valuable insights for physicians to make informed decisions regarding antipsychotic use. Key Points: “Weight gain from medication is one of the most problematic adverse effects facing patients with serious mental illness… It can be a real barrier in getting people to take their meds.” Michel Sabé, MD, corresponding author

In the first update in more than five years, these new guidelines review dosing recommendations for 41 antimicrobials, as applicable for patients with a BMI greater than or equal to 30 kg/m.

Given at a higher dose than for DM2, a weekly semaglutide injection sustainably reduced weight by an average of 15% together with diet. What are the precautions? And what else is on the horizon in the class?

More sedentary time was associated with a higher risk of dry eye disease (DED), particularly for people whose physical activity (PA) levels were below WHO limits. Screen use, however, could account for the observed link and should be emphasized as a potential main confounder since there was no significant association when computer-intensive sitting time was eliminated.